Study of zampilimab for idiopathic pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This trial tests an investigational drug called zampilimab for people with idiopathic pulmonary fibrosis (IPF). It aims to find a safe and effective dose that may slow lung function decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 40 years or older, weigh at least 99 pounds (45 kg), and life expectancy is at least 1 year.
- You must have a confirmed diagnosis of idiopathic pulmonary fibrosis (IPF) from the last 8 years.
- Your lung function test (FVC) must be at least 45% of the normal predicted value.
- You cannot have celiac disease, active lung cancer, or significant emphysema.
- You cannot have had a lung infection or worsening of IPF in the last 4 weeks.
- You must not be taking certain immune-suppressing medicines or high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an inhaled medication for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if the drug is safe and how it works in the body. It might help by targeting the lungs directly with fewer side effects.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
This trial tests an investigational drug called PIPE 791 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug slows lung function decline, and you may continue your current IPF medicine.
This trial studies whether adding azithromycin to standard care can help people whose idiopathic pulmonary fibrosis is starting to flare up (worsen) in the early stages. It’s mainly for adults who are not very sick and cannot require intensive breathing support.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.